Bank of Montreal
EWTX icon

Bank of Montreal’s Edgewise Therapeutics EWTX Stock Holding History

Bank of Montreal’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-316,904
Closed -$2.7M – 3926
2023
Q2 		$2.7M Buy
+316,904
New +$2.67M ﹤0.01% 1651

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of Montreal's EWTX Position: Q3 2023 in Review

Bank of Montreal sold out of Edgewise Therapeutics (EWTX) in Q3 2023, closing a stake of 316,904 shares — an estimated $2.7M sold.

Bank of Montreal first reported a position in EWTX in Q2 2023 and held it in 1 quarter. The position peaked at $2.7M in Q2 2023. 85 funds tracked by Wall St. Rank hold EWTX as of Q3 2023.

  • Bank of Montreal reported no remaining Edgewise Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Bank of Montreal sold 316,904 Edgewise Therapeutics shares in Q3 2023, an estimated $2.7M.
  • Bank of Montreal first reported a position in Edgewise Therapeutics in Q2 2023 and held it in 1 quarter.
  • Bank of Montreal's Edgewise Therapeutics position peaked at $2.7M in Q2 2023.
  • 85 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2023.

Based on Bank of Montreal's 13F filing for Q3 2023, filed 1 Nov 2023.